EvolveImmune receives $18 million milestone payment from ABBV partnership
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- US futures fall on tech selloff as concerns about hawkish Fed, AI spending mount
- SpaceX extends losses after $600 billion wipeout, tech stocks slide again
- Oil steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
EvolveImmune Therapeutics Announces Achievement of Preclinical Milestone in Collaboration with AbbVie
April 28, 2026 7:00 AM EDTBRANFORD, Conn., April 28, 2026 (GLOBE NEWSWIRE) -- EvolveImmune Therapeutics, a clinical-stage immuno-oncology company developing a new class of multi-specific T cell engagers with integrated CD2 costimulation, today announced the nomination of a development candidate against a solid tumor target as part of its ongoing partnership with AbbVie (NYSE: ABBV). Achievement of this pre-defined preclinical milestone triggers an $18 million milestone payment to EvolveImmune.
The program is being advanced under a collaboration and option-to-license agreement to develop multispecific biologics for multiple targets in oncology initiated between... More
